Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tasisulam + pemetrexed
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Tasisulam + pemetrexed** is an experimental combination of two small-molecule anticancer drugs. **Tasisulam** is a synthetic sulfonamide with antineoplastic activity primarily investigated for solid tumor treatment; it induces apoptosis and inhibits tumor angiogenesis by modulating cell cycle and hypoxia signaling pathways. **Pemetrexed** is a multi-targeted antifolate chemotherapy agent approved for mesothelioma and non-small cell lung cancer; its mechanism inhibits folate-dependent enzymes such as thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, thereby blocking DNA and RNA synthesis[1]. This combination is studied for enhanced cytotoxic effects in advanced thoracic malignancies.
- Other names
- tasisulampemetrexed
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on tasisulam + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tasisulam + pemetrexed.